Boobalan Pachaiyappan
Stock Analyst at Roth Capital
(4.30)
# 549
Out of 5,090 analysts
23
Total ratings
52.63%
Success rate
24.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CING Cingulate | Maintains: Buy | $17 → $16 | $3.99 | +301.00% | 4 | Nov 19, 2025 | |
| PYPD PolyPid | Maintains: Buy | $10 → $9 | $3.97 | +126.70% | 3 | Nov 13, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $12 → $13 | $26.89 | -51.65% | 3 | Nov 12, 2025 | |
| RNA Avidity Biosciences | Initiates: Buy | $62 | $71.63 | -13.44% | 1 | Sep 17, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Reiterates: Buy | $7 → $3 | $0.62 | +386.93% | 2 | Aug 18, 2025 | |
| LGVN Longeveron | Maintains: Buy | $10 → $3 | $0.62 | +387.80% | 2 | Aug 15, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 → $6 | $3.85 | +55.84% | 3 | Aug 13, 2025 | |
| CRVO CervoMed | Reiterates: Buy | $20 → $16 | $8.69 | +84.12% | 4 | Aug 12, 2025 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $10.34 | +180.46% | 1 | Dec 5, 2024 |
Cingulate
Nov 19, 2025
Maintains: Buy
Price Target: $17 → $16
Current: $3.99
Upside: +301.00%
PolyPid
Nov 13, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $3.97
Upside: +126.70%
Capricor Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $12 → $13
Current: $26.89
Upside: -51.65%
Avidity Biosciences
Sep 17, 2025
Initiates: Buy
Price Target: $62
Current: $71.63
Upside: -13.44%
Reviva Pharmaceuticals Holdings
Aug 18, 2025
Reiterates: Buy
Price Target: $7 → $3
Current: $0.62
Upside: +386.93%
Longeveron
Aug 15, 2025
Maintains: Buy
Price Target: $10 → $3
Current: $0.62
Upside: +387.80%
Gain Therapeutics
Aug 13, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $3.85
Upside: +55.84%
CervoMed
Aug 12, 2025
Reiterates: Buy
Price Target: $20 → $16
Current: $8.69
Upside: +84.12%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $10.34
Upside: +180.46%